REVA Medical Inc. Announces Dr. David Muller as Co-Principal Investigator for RESTORE II Clinical Trial
9/13/2012 9:34:27 AM
SAN DIEGO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce the appointment of Dr. David Muller, Director, Cardiac Catheterization at St. Vincent's Hospital, Sydney, as co-principal investigator for the Company's upcoming RESTORE II clinical trial, which is expected to begin enrolling patients in the first quarter of 2013. Dr. Alexandre Abizaid of Dante Pazzanese Institute of Cardiology, who successfully led REVA's initial RESTORE pilot study, will continue as a co-principal investigator with Dr. Muller for the RESTORE II trial.